�ݺ�ߣshows by User: zamrankhan1

�ݺ�ߣshows by User: zamrankhan1 / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: zamrankhan1 / Wed, 02 Oct 2024 15:56:15 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: zamrankhan1 pharmacovigilance introduction & imp terms.pptx /slideshow/pharmacovigilance-introduction-imp-terms-pptx/272149677 pv-241002155615-439d0de4
Definition: Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Importance: Ensures patient safety and the efficacy of drugs in clinical use. Adverse Drug Reaction (ADR): Any response to a drug that is harmful and unintended. Signal Detection: Process of identifying new safety information from data sources. Risk Management: Measures taken to mitigate identified risks. Objectives of Pharmacovigilance To identify and assess adverse drug reactions (ADRs). To ensure the benefits of a drug outweigh its risks. To contribute to the safe and effective use of medicines. To provide information for the rational use of drugs. Core Activities in Pharmacovigilance Adverse Event Reporting: Documenting and reporting adverse drug reactions (ADRs). Signal Detection: Identifying new risks or rare adverse effects. Risk Assessment and Management: Analyzing risk-benefit ratio of drugs. Communication: Informing healthcare professionals and the public about risks. Definition: Dechallenge refers to the process of stopping or withdrawing a drug after an adverse event has been identified, in order to observe whether the adverse event improves or resolves. Purpose: It helps establish a causal relationship between the drug and the adverse event by monitoring whether the symptoms diminish after the drug is discontinued. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. Establishing a causal relationship is critical for understanding drug safety and making informed decisions about medication use. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. ]]>
Definition: Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Importance: Ensures patient safety and the efficacy of drugs in clinical use. Adverse Drug Reaction (ADR): Any response to a drug that is harmful and unintended. Signal Detection: Process of identifying new safety information from data sources. Risk Management: Measures taken to mitigate identified risks. Objectives of Pharmacovigilance To identify and assess adverse drug reactions (ADRs). To ensure the benefits of a drug outweigh its risks. To contribute to the safe and effective use of medicines. To provide information for the rational use of drugs. Core Activities in Pharmacovigilance Adverse Event Reporting: Documenting and reporting adverse drug reactions (ADRs). Signal Detection: Identifying new risks or rare adverse effects. Risk Assessment and Management: Analyzing risk-benefit ratio of drugs. Communication: Informing healthcare professionals and the public about risks. Definition: Dechallenge refers to the process of stopping or withdrawing a drug after an adverse event has been identified, in order to observe whether the adverse event improves or resolves. Purpose: It helps establish a causal relationship between the drug and the adverse event by monitoring whether the symptoms diminish after the drug is discontinued. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. Establishing a causal relationship is critical for understanding drug safety and making informed decisions about medication use. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. ]]> Wed, 02 Oct 2024 15:56:15 GMT /slideshow/pharmacovigilance-introduction-imp-terms-pptx/272149677 zamrankhan1@slideshare.net(zamrankhan1) pharmacovigilance introduction & imp terms.pptx zamrankhan1 Definition: Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Importance: Ensures patient safety and the efficacy of drugs in clinical use. Adverse Drug Reaction (ADR): Any response to a drug that is harmful and unintended. Signal Detection: Process of identifying new safety information from data sources. Risk Management: Measures taken to mitigate identified risks. Objectives of Pharmacovigilance To identify and assess adverse drug reactions (ADRs). To ensure the benefits of a drug outweigh its risks. To contribute to the safe and effective use of medicines. To provide information for the rational use of drugs. Core Activities in Pharmacovigilance Adverse Event Reporting: Documenting and reporting adverse drug reactions (ADRs). Signal Detection: Identifying new risks or rare adverse effects. Risk Assessment and Management: Analyzing risk-benefit ratio of drugs. Communication: Informing healthcare professionals and the public about risks. Definition: Dechallenge refers to the process of stopping or withdrawing a drug after an adverse event has been identified, in order to observe whether the adverse event improves or resolves. Purpose: It helps establish a causal relationship between the drug and the adverse event by monitoring whether the symptoms diminish after the drug is discontinued. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. Establishing a causal relationship is critical for understanding drug safety and making informed decisions about medication use. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pv-241002155615-439d0de4-thumbnail.jpg?width=120&height=120&fit=bounds" /> Definition: Pharmacovigilance (PV) is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. Importance: Ensures patient safety and the efficacy of drugs in clinical use. Adverse Drug Reaction (ADR): Any response to a drug that is harmful and unintended. Signal Detection: Process of identifying new safety information from data sources. Risk Management: Measures taken to mitigate identified risks. Objectives of Pharmacovigilance To identify and assess adverse drug reactions (ADRs). To ensure the benefits of a drug outweigh its risks. To contribute to the safe and effective use of medicines. To provide information for the rational use of drugs. Core Activities in Pharmacovigilance Adverse Event Reporting: Documenting and reporting adverse drug reactions (ADRs). Signal Detection: Identifying new risks or rare adverse effects. Risk Assessment and Management: Analyzing risk-benefit ratio of drugs. Communication: Informing healthcare professionals and the public about risks. Definition: Dechallenge refers to the process of stopping or withdrawing a drug after an adverse event has been identified, in order to observe whether the adverse event improves or resolves. Purpose: It helps establish a causal relationship between the drug and the adverse event by monitoring whether the symptoms diminish after the drug is discontinued. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. Definition: Rechallenge refers to the re-administration of a drug after it was previously discontinued due to an adverse event, in order to observe whether the adverse event recurs. Purpose: It is used to further confirm a causal relationship between the drug and the adverse event by determining if the adverse event reappears when the drug is given again. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event. Establishing a causal relationship is critical for understanding drug safety and making informed decisions about medication use. A causal relationship in pharmacovigilance refers to the connection between a drug and an adverse event, indicating that the drug is responsible for causing the adverse event.

pharmacovigilance introduction & imp terms.pptx from zamran khan

]]> 46 0 https://cdn.slidesharecdn.com/ss_thumbnails/pv-241002155615-439d0de4-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 PHASES OF CLINICAL DATA. MANAGEMENT.pptx /slideshow/phases-of-clinical-data-management-pptx/271995286 phasesofcdm-240924153155-60fb9d57
Clinical Data Management (CDM) refers to the process of collecting, cleaning, and managing clinical trial data in compliance with regulatory standards. Purpose: To ensure high-quality, reliable data that supports the evaluation of drug efficacy and safety. Brief overview of the phases involved in CDM: START UP PHASE CONDUCT PHASE CLOSE OUT PHASE ]]>
Clinical Data Management (CDM) refers to the process of collecting, cleaning, and managing clinical trial data in compliance with regulatory standards. Purpose: To ensure high-quality, reliable data that supports the evaluation of drug efficacy and safety. Brief overview of the phases involved in CDM: START UP PHASE CONDUCT PHASE CLOSE OUT PHASE ]]> Tue, 24 Sep 2024 15:31:55 GMT /slideshow/phases-of-clinical-data-management-pptx/271995286 zamrankhan1@slideshare.net(zamrankhan1) PHASES OF CLINICAL DATA. MANAGEMENT.pptx zamrankhan1 Clinical Data Management (CDM) refers to the process of collecting, cleaning, and managing clinical trial data in compliance with regulatory standards. Purpose: To ensure high-quality, reliable data that supports the evaluation of drug efficacy and safety. Brief overview of the phases involved in CDM: START UP PHASE CONDUCT PHASE CLOSE OUT PHASE <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/phasesofcdm-240924153155-60fb9d57-thumbnail.jpg?width=120&height=120&fit=bounds" /> Clinical Data Management (CDM) refers to the process of collecting, cleaning, and managing clinical trial data in compliance with regulatory standards. Purpose: To ensure high-quality, reliable data that supports the evaluation of drug efficacy and safety. Brief overview of the phases involved in CDM: START UP PHASE CONDUCT PHASE CLOSE OUT PHASE

PHASES OF CLINICAL DATA. MANAGEMENT.pptx from zamran khan

]]> 192 0 https://cdn.slidesharecdn.com/ss_thumbnails/phasesofcdm-240924153155-60fb9d57-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 THE ..13- PRINCIPLES- OF- ICH-GCP .pptx /slideshow/the-13-principles-of-ich-gcp-pptx/271555408 ichgcpprinciples-240904100536-10a7ecd7
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines are a set of internationally recognized standards for conducting clinical trials. The 13 principles of ICH GCP are designed to ensure the safety, rights, and well-being of trial participants, and to maintain the integrity and credibility of clinical trial data. Here’s a detailed explanation of each principle based on ICH GCP E6(R3) ]]>
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines are a set of internationally recognized standards for conducting clinical trials. The 13 principles of ICH GCP are designed to ensure the safety, rights, and well-being of trial participants, and to maintain the integrity and credibility of clinical trial data. Here’s a detailed explanation of each principle based on ICH GCP E6(R3) ]]> Wed, 04 Sep 2024 10:05:36 GMT /slideshow/the-13-principles-of-ich-gcp-pptx/271555408 zamrankhan1@slideshare.net(zamrankhan1) THE ..13- PRINCIPLES- OF- ICH-GCP .pptx zamrankhan1 The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines are a set of internationally recognized standards for conducting clinical trials. The 13 principles of ICH GCP are designed to ensure the safety, rights, and well-being of trial participants, and to maintain the integrity and credibility of clinical trial data. Here’s a detailed explanation of each principle based on ICH GCP E6(R3) <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ichgcpprinciples-240904100536-10a7ecd7-thumbnail.jpg?width=120&height=120&fit=bounds" /> The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines are a set of internationally recognized standards for conducting clinical trials. The 13 principles of ICH GCP are designed to ensure the safety, rights, and well-being of trial participants, and to maintain the integrity and credibility of clinical trial data. Here’s a detailed explanation of each principle based on ICH GCP E6(R3)

THE ..13- PRINCIPLES- OF- ICH-GCP .pptx from zamran khan

]]> 717 0 https://cdn.slidesharecdn.com/ss_thumbnails/ichgcpprinciples-240904100536-10a7ecd7-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Seminar on entreprenship /slideshow/seminar-on-entreprenship/236807668 seminaronentreprenship-200711092704
by zamran khan]]>
by zamran khan]]> Sat, 11 Jul 2020 09:27:04 GMT /slideshow/seminar-on-entreprenship/236807668 zamrankhan1@slideshare.net(zamrankhan1) Seminar on entreprenship zamrankhan1 by zamran khan <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/seminaronentreprenship-200711092704-thumbnail.jpg?width=120&height=120&fit=bounds" /> by zamran khan

Seminar on entreprenship from zamran khan

]]> 300 0 https://cdn.slidesharecdn.com/ss_thumbnails/seminaronentreprenship-200711092704-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Seminar on pgr in plants /slideshow/seminar-on-pgr-in-plants/207771470 seminaronpgrinplants-191219150142
seminar on plant hormones.]]>
seminar on plant hormones.]]> Thu, 19 Dec 2019 15:01:42 GMT /slideshow/seminar-on-pgr-in-plants/207771470 zamrankhan1@slideshare.net(zamrankhan1) Seminar on pgr in plants zamrankhan1 seminar on plant hormones. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/seminaronpgrinplants-191219150142-thumbnail.jpg?width=120&height=120&fit=bounds" /> seminar on plant hormones.

Seminar on pgr in plants from zamran khan

]]> 3453 3 https://cdn.slidesharecdn.com/ss_thumbnails/seminaronpgrinplants-191219150142-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 303 genetic engineering /slideshow/bth-303-genetic-engineering/175203561 bth303geneticengineering-190923185412
for Bangalore University M.Sc Biotechnology 3 rd sem students]]>
for Bangalore University M.Sc Biotechnology 3 rd sem students]]> Mon, 23 Sep 2019 18:54:12 GMT /slideshow/bth-303-genetic-engineering/175203561 zamrankhan1@slideshare.net(zamrankhan1) Bth 303 genetic engineering zamrankhan1 for Bangalore University M.Sc Biotechnology 3 rd sem students <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth303geneticengineering-190923185412-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore University M.Sc Biotechnology 3 rd sem students

Bth 303 genetic engineering from zamran khan

]]> 2560 9 https://cdn.slidesharecdn.com/ss_thumbnails/bth303geneticengineering-190923185412-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 301 plant and agricultural biotechnology /zamrankhan1/bth-301-plant-and-agricultural-biotechnology bth301plantandagriculturalbiotechnology-190923185351
for Bangalore University M.Sc Biotechnology 3 rd sem students]]>
for Bangalore University M.Sc Biotechnology 3 rd sem students]]> Mon, 23 Sep 2019 18:53:51 GMT /zamrankhan1/bth-301-plant-and-agricultural-biotechnology zamrankhan1@slideshare.net(zamrankhan1) Bth 301 plant and agricultural biotechnology zamrankhan1 for Bangalore University M.Sc Biotechnology 3 rd sem students <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth301plantandagriculturalbiotechnology-190923185351-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore University M.Sc Biotechnology 3 rd sem students

Bth 301 plant and agricultural biotechnology from zamran khan

]]> 1701 4 https://cdn.slidesharecdn.com/ss_thumbnails/bth301plantandagriculturalbiotechnology-190923185351-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 2017 pg 240 to 244, 651 to 654 /slideshow/2017-pg-240-to-244-651-to-654/154530748 2017pg-240to244651to654-190709184934
Msc biotechnology 2nd sem Bangalore university 2017 question papers.]]>
Msc biotechnology 2nd sem Bangalore university 2017 question papers.]]> Tue, 09 Jul 2019 18:49:34 GMT /slideshow/2017-pg-240-to-244-651-to-654/154530748 zamrankhan1@slideshare.net(zamrankhan1) 2017 pg 240 to 244, 651 to 654 zamrankhan1 Msc biotechnology 2nd sem Bangalore university 2017 question papers. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/2017pg-240to244651to654-190709184934-thumbnail.jpg?width=120&height=120&fit=bounds" /> Msc biotechnology 2nd sem Bangalore university 2017 question papers.

2017 pg 240 to 244, 651 to 654 from zamran khan

]]> 136 1 https://cdn.slidesharecdn.com/ss_thumbnails/2017pg-240to244651to654-190709184934-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Seminar on green house effect /zamrankhan1/seminar-on-green-house-effect seminaronghg-190524181935
by zamran khan]]>
by zamran khan]]> Fri, 24 May 2019 18:19:35 GMT /zamrankhan1/seminar-on-green-house-effect zamrankhan1@slideshare.net(zamrankhan1) Seminar on green house effect zamrankhan1 by zamran khan <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/seminaronghg-190524181935-thumbnail.jpg?width=120&height=120&fit=bounds" /> by zamran khan

Seminar on green house effect from zamran khan

]]> 15435 3 https://cdn.slidesharecdn.com/ss_thumbnails/seminaronghg-190524181935-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 103 general microbiology /slideshow/bth-103-general-microbiology/141488411 bth103generalmicrobiology-190421182551
for Bangalore university M.Sc Biotechnology 1 st sem students ]]>
for Bangalore university M.Sc Biotechnology 1 st sem students ]]> Sun, 21 Apr 2019 18:25:51 GMT /slideshow/bth-103-general-microbiology/141488411 zamrankhan1@slideshare.net(zamrankhan1) Bth 103 general microbiology zamrankhan1 for Bangalore university M.Sc Biotechnology 1 st sem students <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth103generalmicrobiology-190421182551-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university M.Sc Biotechnology 1 st sem students

Bth 103 general microbiology from zamran khan

]]> 2134 13 https://cdn.slidesharecdn.com/ss_thumbnails/bth103generalmicrobiology-190421182551-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 101 cell biology /slideshow/bth-101-cell-biology/140084465 bth101cellbiology-190408193457
for Bangalore university M.Sc Biotechnology 1 st sem students cell biology]]>
for Bangalore university M.Sc Biotechnology 1 st sem students cell biology]]> Mon, 08 Apr 2019 19:34:57 GMT /slideshow/bth-101-cell-biology/140084465 zamrankhan1@slideshare.net(zamrankhan1) Bth 101 cell biology zamrankhan1 for Bangalore university M.Sc Biotechnology 1 st sem students cell biology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth101cellbiology-190408193457-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university M.Sc Biotechnology 1 st sem students cell biology

Bth 101 cell biology from zamran khan

]]> 1566 5 https://cdn.slidesharecdn.com/ss_thumbnails/bth101cellbiology-190408193457-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bts 205 bioinformatics /zamrankhan1/bts-205-bioinformatics bts205bioinformatics-190404171816
for Bangalore university Msc biotechnology 2nd sem students. All the best.]]>
for Bangalore university Msc biotechnology 2nd sem students. All the best.]]> Thu, 04 Apr 2019 17:18:16 GMT /zamrankhan1/bts-205-bioinformatics zamrankhan1@slideshare.net(zamrankhan1) Bts 205 bioinformatics zamrankhan1 for Bangalore university Msc biotechnology 2nd sem students. All the best. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bts205bioinformatics-190404171816-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university Msc biotechnology 2nd sem students. All the best.

Bts 205 bioinformatics from zamran khan

]]> 1292 4 https://cdn.slidesharecdn.com/ss_thumbnails/bts205bioinformatics-190404171816-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 204 environmental biotechnology /slideshow/bth-204-environmental-biotechnology/139598231 bth204environmentalbiotechnology-190404171749
for Bangalore university Msc biotechnology 2nd sem students. All the best]]>
for Bangalore university Msc biotechnology 2nd sem students. All the best]]> Thu, 04 Apr 2019 17:17:49 GMT /slideshow/bth-204-environmental-biotechnology/139598231 zamrankhan1@slideshare.net(zamrankhan1) Bth 204 environmental biotechnology zamrankhan1 for Bangalore university Msc biotechnology 2nd sem students. All the best <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth204environmentalbiotechnology-190404171749-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university Msc biotechnology 2nd sem students. All the best

Bth 204 environmental biotechnology from zamran khan

]]> 3170 2 https://cdn.slidesharecdn.com/ss_thumbnails/bth204environmentalbiotechnology-190404171749-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 202 molecular biology /slideshow/bth-202-molecular-biology/139598112 bth202molecularbiology-190404171711
for Bangalore university Msc biotechnology 2nd sem students. All the best]]>
for Bangalore university Msc biotechnology 2nd sem students. All the best]]> Thu, 04 Apr 2019 17:17:10 GMT /slideshow/bth-202-molecular-biology/139598112 zamrankhan1@slideshare.net(zamrankhan1) Bth 202 molecular biology zamrankhan1 for Bangalore university Msc biotechnology 2nd sem students. All the best <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth202molecularbiology-190404171711-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university Msc biotechnology 2nd sem students. All the best

Bth 202 molecular biology from zamran khan

]]> 3087 3 https://cdn.slidesharecdn.com/ss_thumbnails/bth202molecularbiology-190404171711-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Bth 201 enzymology and biochemical techniques /slideshow/bth-201-enzymology-and-biochemical-techniques/139598055 bth201enzymologyandbiochemicaltechniques-190404171652
for Bangalore university Msc biotechnology 2nd sem students. All the best ]]>
for Bangalore university Msc biotechnology 2nd sem students. All the best ]]> Thu, 04 Apr 2019 17:16:52 GMT /slideshow/bth-201-enzymology-and-biochemical-techniques/139598055 zamrankhan1@slideshare.net(zamrankhan1) Bth 201 enzymology and biochemical techniques zamrankhan1 for Bangalore university Msc biotechnology 2nd sem students. All the best <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bth201enzymologyandbiochemicaltechniques-190404171652-thumbnail.jpg?width=120&height=120&fit=bounds" /> for Bangalore university Msc biotechnology 2nd sem students. All the best

Bth 201 enzymology and biochemical techniques from zamran khan

]]> 2059 5 https://cdn.slidesharecdn.com/ss_thumbnails/bth201enzymologyandbiochemicaltechniques-190404171652-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Compound lipids. /slideshow/compound-lipids-127331273/127331273 compoundlipids-190105112840
Presented by Zamran Khan Msc biotechnology ]]>
Presented by Zamran Khan Msc biotechnology ]]> Sat, 05 Jan 2019 11:28:40 GMT /slideshow/compound-lipids-127331273/127331273 zamrankhan1@slideshare.net(zamrankhan1) Compound lipids. zamrankhan1 Presented by Zamran Khan Msc biotechnology <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/compoundlipids-190105112840-thumbnail.jpg?width=120&height=120&fit=bounds" /> Presented by Zamran Khan Msc biotechnology

Compound lipids. from zamran khan

]]> 30273 7 https://cdn.slidesharecdn.com/ss_thumbnails/compoundlipids-190105112840-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/pv-241002155615-439d0de4-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/pharmacovigilance-introduction-imp-terms-pptx/272149677 pharmacovigilance intr... https://cdn.slidesharecdn.com/ss_thumbnails/phasesofcdm-240924153155-60fb9d57-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/phases-of-clinical-data-management-pptx/271995286 PHASES OF CLINICAL DAT... https://cdn.slidesharecdn.com/ss_thumbnails/ichgcpprinciples-240904100536-10a7ecd7-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/the-13-principles-of-ich-gcp-pptx/271555408 THE ..13- PRINCIPLES- ...